Influx targets Rs 400 crore to Rs 500 crore within three years

Influx Healthtech Limited is targeting Rs 400 crore to Rs 500 crore of revenue within about three years from capacity that management says will be 2.5 times its current machinery capacity, led by a 75,000-square-foot plant targeted for commercial production around January after licensing.

When will Influx commission its new manufacturing plant?

Influx expects the new facility to be ready in December 2026 and is targeting commercial production around January, subject to receiving a Food Safety and Standards Authority of India, or FSSAI, manufacturing licence. Management said civil work at the ground-plus-four-floor facility was complete, while internal partitions and flooring were under way. It had also applied for partial occupancy approval before starting the licensing procedure.

The project took a few additional months because the civil scope increased from an initially discussed 35,000 square feet to about 70,000 to 75,000 square feet, according to management. Management said the larger building required further approvals, although machinery installation plans remained unchanged. It also said funds were diverted from the veterinary segment to the expanded facility, making the January start-up a management target rather than a completed milestone.

What capacity will the new Influx plant add?

Influx says the facility will increase machinery capacity by about 2.5 times and initially use around 35,000 to 40,000 square feet of the 75,000-square-foot structure. Management said the remaining space removes the immediate need for another site and could support future brownfield expansion. It identified about 12,000 to 24,000 square feet for potential additional machinery when demand requires it.

The plant is designed to produce more than 5 lakh tablets per day per shift, equivalent to about 15,000 bottles daily at 30 units per bottle, and a further 15,000 bars per day. Influx has installed automated lines for multi-layer wafer bars and machines for ready-to-drink blister shots. Management also linked the FSSAI licence to a proposed wellness-product range using aseptic packaging and retort manufacturing processes.

Influx is separately expanding pet-nutrition output from 16 to 18 tonnes a month towards 25 tonnes a month. A pet-food extrusion line is intended to increase hourly production from 100 to 150 kilograms to 1,000 kilograms, while fabrication and installation remained under way. Management expected the pet line to become operational within a couple of months of the November 5, 2026 earnings call.

How does Influx plan to reach Rs 400 crore to Rs 500 crore revenue?

Influx management said the currently installed machinery could support Rs 400 crore to Rs 500 crore of revenue at full utilisation over the next two to three years. In another answer, management put the expectation at Rs 450 crore to Rs 500 crore in 2028, about 2.5 to three years away. The range is management's capacity-led expectation, not reported revenue or a target assigned to a specific financial year.

Management expects the new unit to add about 20% to 25% over the previous quarter after commissioning. It illustrated that potential by saying revenue of Rs 100 crore could become Rs 125 crore in the following quarter, with Rs 20 crore to Rs 25 crore of the increase coming from the new plant. For FY27, Influx said it would try to cross Rs 200 crore of revenue and was on track at the current run rate, without giving a firm commitment.

Nutraceuticals supplied around Rs 75.3 crore of Influx's around Rs 85.4 crore revenue from operations in the first half of FY27, making it the principal segment behind the expansion case. Revenue increased 27.9% year on year. Earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 25.2% to around Rs 18.3 crore, while the EBITDA margin declined 50 basis points year on year to 21.5%.

What demand could fill Influx's added capacity?

Influx plans to use a combination of higher volumes from existing customers and new customer acquisition to fill the added capacity. Management named Fast&Up as a customer that had placed liquid-fill orders and was awaiting the expansion. It also said Carbamide Forte, described as its top client, had communicated a requirement for three times its current capacity, though Influx does not generally operate with a formal order book.

Influx reported more than 500 clients, an 88% retention rate and over 2,300 stock-keeping units, or SKUs, across healthcare and wellness categories. Management said it was focusing more closely on larger customers, explaining why a period with around 500 clients could generate more revenue than an earlier period cited by an analyst with roughly 700 clients. It nevertheless said the new facility would serve a mix of larger, medium-scale and smaller customers.

Management plans to target 21 Code of Federal Regulations, or 21 CFR, compliance at the new plant to pursue larger and multinational customers. It said new customers may inspect or audit the facility, while existing customers may not need further plant approval. Influx also said its Quick Snap single-dose format had secured initial orders and that cosmetic revenue reached around Rs 6.9 crore in H1 FY27, compared with Rs 3.2 crore cited by management for the comparable earlier period.

What execution factors should readers track?

The central near-term variable is the FSSAI licence, which management said generally takes 15 to 20 days or about one month after a plant is ready, depending on regulatory queries. Management said research and development trials and installation work could continue during that period. It did not identify approval from the US Food and Drug Administration as necessary to start commercial production at the facility.

Influx incurred around Rs 19.9 crore of capital expenditure on property, plant, equipment and intangible assets in H1 FY27. It reported around Rs 9.6 crore in cash and cash equivalents and around Rs 7.2 crore of net cash generated from operations in the same six months. Management said the company had operated at 90% capacity in the prior year and had added machinery at its older unit to bridge the two-to-three-month gap before the new facility starts.

Conclusion

Influx's Rs 400 crore to Rs 500 crore revenue ambition depends on converting a 2.5-times increase in machinery capacity into sustained production across nutraceuticals, bars, beverages and pet nutrition. The company reported around Rs 85.4 crore in H1 FY27 revenue, of which nutraceuticals accounted for around Rs 75.3 crore, while management identified existing clients and new customer additions as sources of utilisation.

The next milestones are the December 2026 plant-readiness target, FSSAI licensing and management's target for commercial production around January. Readers should also watch whether the new unit produces the stated 20% to 25% quarter-on-quarter uplift and whether customer inspections, audits and utilisation support the longer-term revenue range.